✨ Free AI Report
Evogene Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Evogene Ltd.
Company Research

Evogene Ltd.: Business Overview, Financials & Competitive Analysis

Evogene Ltd. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Compelling AI-platform technology for small-molecule discovery with established partnerships, but cash burn and limited revenue near-term limit upside without significant funding or partnership success. Evogene possesses strong AI-driven technology with demonstrated pharma partnerships and clinical-stage assets, but faces significant financial headwinds. Net loss for Q1 2026 was approximately $5.9 million.

What is Evogene Ltd.'s industry? Evogene Ltd. (evogene.com) operates in Drug Discovery Services. AskCyborg classifies Evogene Ltd. under Drug Discovery Services in its company registry.

Evogene Ltd. is a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass...

5/ 10Mixed

Cyborg Score thesis

Compelling AI-platform technology for small-molecule discovery with established partnerships, but cash burn and limited revenue...

Read the full analyst-debate transcript →
Industry Drug Discovery Services
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Evogene Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Evogene Ltd.

AskCyborg analysts argue the bull and bear cases for Evogene Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Evogene Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Evogene Ltd. Overview

Pro stress-test →

Evogene Ltd. is a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. The company underwent a strategic transformation initiated in 2025, now focused on execution and advancing its tech engine for small-molecule discovery and optimization through collaborations and internal programs.

Strategic Profile

Pro stress-test →

ChemPass AI™'s competitive advantage lies in its ability to generate novel molecules while optimizing multiple critical parameters from the earliest stages of design. This powerful platform significantly improves success rates while reducing development time and costs. The company is expanding its pharma pipeline while maintaining agricultural applications as a secondary focus area.

Competitive Landscape

Pro stress-test →

Evogene operates with proprietary tech-engines including MicroBoost AI, ChemPass AI, and GeneRator AI focused on microbes, small molecules, and genetic elements, used internally through subsidiaries and strategic collaborations. Primary competitors include established computational drug discovery platforms from larger pharma and dedicated AI biotech companies, with differentiation centered on multi-parameter molecular optimization.

Industry Context

Evogene Ltd. operates in Drug Discovery Services.

Key facts

Founded: 2000s · Headquarters: Rehovot, Israel · Employees: N/A · Revenue: $3.9M (2025) · Market cap: $9.5M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Evogene Ltd..

  • In February 2026, Biomica (Evogene subsidiary) granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license for BMC128, a microbiome-based therapeutic showing promise in renal and lung cancer, bringing China's clinical capabilities with Israel's microbiome science innovation
  • Dr. Olga Nissan was appointed Vice President of Business Development effective January 2026, a seasoned biotech executive with experience in R&D, clinical development, and AI-enabled drug discovery
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Q1 2026 financial results reported with $5.9 million net loss; CEO emphasized execution on ChemPass AI advancement and pipeline expansion
  • March 2026Presented pharma discovery achievements at BIO-Europe Spring 2026 conference highlighting AI-driven small-molecule discovery capabilities
  • +2 moreTrack every material event for Evogene Ltd. as it happens. Explore monitoring →
Get alerted when Evogene Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DeepMind for drug discoveryAI-powered protein structure prediction and molecular design→AtomwiseAI platform for small-molecule drug discovery→ExscientiaAI-powered drug discovery and optimization platform→Insilico MedicineGenerative AI for drug discovery and biomarker development→

Compare Evogene Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Evogene Ltd. operates in Drug Discovery Services. See how the rest of the sector scores on the Cyborg framework.

Browse Drug Discovery Services research →
NEW · MCP server

Ask your AI assistant about Evogene Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Evogene Ltd. and its top competitor on Cyborg Score”
“What did Evogene Ltd. do this quarter?”
“Is Evogene Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Evogene Ltd. do?+
Evogene Ltd. is a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass...
What is Evogene Ltd.'s Cyborg Score?+
Evogene Ltd. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Evogene Ltd.'s main competitors?+
Named competitors include DeepMind for drug discovery, Atomwise, Exscientia, Insilico Medicine. The full competitive landscape is in the AskCyborg report.
How can I get the full Evogene Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Evogene Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Evogene Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.